Teijin Limited announced today its agreement with UK pharmaceutical company Sigma-Tau Pharma Ltd., part of the Sigma-Tau Group , for exclusive development and distribution rights in Japan to EZN-2279, a therapeutic agent for adenosine deaminase deficiency in patients with severe combined immune deficiency .
http://ift.tt/1mxIDCJ
http://ift.tt/1mxIDCJ
No comments:
Post a Comment